Clinical Trial Update: Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ripasudil 0.4% eye drops for Fuchs' Endothelial Corneal Dystrophy; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Corneal Dystrophy

Drugs mentioned

• Ripasudil 0.4% Eye Drops (ripasudil)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Fuchs' Endothelial Dystrophy, Fuchs Dystrophy | Phase 2 | Status: UNKNOWN